OTSUKA CORPORATION (4768.T) Latest Company News

Aug 20, 2026, 04:04 UTC
Infomart announced strengthening its collaboration with Otsuka Corporation to promote DX in the manufacturing and wholesale industries, adding its TANOMU ordering system and BP Storage AI-OCR services to Otsuka's 'Tayoreru' business support service.
Source:
Aug 4, 2026, 03:40 UTC
Otsuka Holdings presented new Phase 3 trial data for its IgA nephropathy drug sibeprenlimab at GlomCon Hawaii 2026, showing improved eGFR and stabilization of kidney function over two years compared to placebo.
Source:
- s.kabutan.jp
- s.kabutan.jp
Aug 3, 2026, 09:08 UTC
Taiho Pharmaceutical and Fujifilm announced on August 3, 2026, a collaboration to develop manufacturing technology for antibody-drug conjugates (ADCs) to ensure stable production of high-quality products.
Source:
- nikkei.com
Aug 3, 2026, 07:35 UTC
Otsuka Shokai revised its full-year ordinary profit forecast upward to a 5% increase, achieving a record high and increasing dividends by 10 yen.
Source:
Aug 3, 2026, 06:30 UTC
Otsuka Corporation increased its annual dividend forecast for fiscal 2026 from 95 yen to 105 yen per share, up from 90 yen in the previous year.
Source:
Aug 3, 2026, 06:30 UTC
Otsuka Corporation announced its first-half 2026 results on August 3, reporting a 9.4% year-on-year increase in recurring profit to 54.8 billion yen, reversing its previous forecast of a decline.
Source:
- s.kabutan.jp
- s.kabutan.jp
Jul 31, 2026, 04:30 UTC
Otsuka Holdings increased its annual dividend forecast for fiscal year 2026 from 140 yen to 200 yen per share.
Source:
- s.kabutan.jp
Jul 27, 2026, 23:30 UTC
Otsuka Holdings revised upward its first-half net profit forecast for the fiscal year ending December 2026, from 128 billion yen to 215 billion yen, a 68% increase, now expecting a 23.9% year-on-year rise.
Source:
Jul 27, 2026, 03:35 UTC
Otsuka Pharmaceutical launched a powder stick type of Pocari Sweat Ion Water for 500ml my-bottles.
Source:
- nikkei.com
Jul 27, 2026, 03:12 UTC
Otsuka Pharmaceutical received FDA approval for its ADHD drug Centanafadine (product name Syntriol) and plans to launch it in the US by mid-2026.
Source:
- nikkei.com
Jul 23, 2026, 08:58 UTC
Otsuka Pharmaceutical announced price increases for Calorie Mate and Soyjoy products effective November 2, 2026, with a maximum increase of 16.7% in manufacturer's suggested retail price.
Source:
- nikkei.com
Jul 15, 2026, 08:46 UTC
Prodelight announced that the account count for its cloud PBX 'INNOVERA' exceeded 55,000 and the number of continuing corporate users surpassed 2,200.
Source:
- s.kabutan.jp

4768.T

Infomart announced strengthening its collaboration with Otsuka Corporation to promote DX in the manufacturing and wholesale industries, adding its TANOMU ordering system and BP Storage AI-OCR services to Otsuka's 'Tayoreru' business support service.

Otsuka Holdings presented new Phase 3 trial data for its IgA nephropathy drug sibeprenlimab at GlomCon Hawaii 2026, showing improved eGFR and stabilization of kidney function over two years compared to placebo.

Taiho Pharmaceutical and Fujifilm announced on August 3, 2026, a collaboration to develop manufacturing technology for antibody-drug conjugates (ADCs) to ensure stable production of high-quality products.

Otsuka Shokai revised its full-year ordinary profit forecast upward to a 5% increase, achieving a record high and increasing dividends by 10 yen.

Otsuka Corporation increased its annual dividend forecast for fiscal 2026 from 95 yen to 105 yen per share, up from 90 yen in the previous year.

Otsuka Corporation announced its first-half 2026 results on August 3, reporting a 9.4% year-on-year increase in recurring profit to 54.8 billion yen, reversing its previous forecast of a decline.

Otsuka Holdings increased its annual dividend forecast for fiscal year 2026 from 140 yen to 200 yen per share.

Otsuka Holdings revised upward its first-half net profit forecast for the fiscal year ending December 2026, from 128 billion yen to 215 billion yen, a 68% increase, now expecting a 23.9% year-on-year rise.

Otsuka Pharmaceutical launched a powder stick type of Pocari Sweat Ion Water for 500ml my-bottles.

Otsuka Pharmaceutical received FDA approval for its ADHD drug Centanafadine (product name Syntriol) and plans to launch it in the US by mid-2026.

Otsuka Pharmaceutical announced price increases for Calorie Mate and Soyjoy products effective November 2, 2026, with a maximum increase of 16.7% in manufacturer's suggested retail price.

Prodelight announced that the account count for its cloud PBX 'INNOVERA' exceeded 55,000 and the number of continuing corporate users surpassed 2,200.